Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284764 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2ACACBACACANQO2HDAC3 | |
| SCHEMBL5663889 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2ACACBACACANQO2L3MBTL1 | |
| SCHEMBL16152246 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2ACACBACACANQO2L3MBTL1 | |
| SCHEMBL265731 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2ACACBACACANQO2L3MBTL1 | |
| SCHEMBL284884 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNATP53BP1 | |
| SCHEMBL1754810 | 0.87 | POLB (0.58) | SMN1; SMN2DGAT1POLBMALT1IDO1 | |
| SCHEMBL14679371 | 0.86 | NPC1 (0.57) | SMN1; SMN2HDAC8HDAC6KMT2APOLB | |
| SCHEMBL13383556 | 0.86 | KDM4E (0.63) | SMN1; SMN2ACACBACACADGAT1LMNA | |
| SCHEMBL5896700 | 0.85 | DGAT1 (0.53) | SMN1; SMN2NR1H4L3MBTL1DGAT1KMT2A | |
| SCHEMBL5663105 | 0.85 | TP53BP1 (0.62) | SMN1; SMN2ACACBACACANQO2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2964654-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| US-7659403-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-[methyl(3-(2-[(thiophen-2-ylmethyl)amino]ethylcarbamoyl)benzoyl)amino]ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7632847-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632847-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-06 | — | — | US | disclosed |
| WO-2006098997-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099091-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205777-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | SMN1; SMN2 3701/4885NR1H4 132/4885ACACB 1799/4885 |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | SMN1; SMN2 3695/4885NR1H4 130/4885ACACB 1916/4885 |
| US-20060205777-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | SMN1; SMN2 3701/4885NR1H4 132/4885ACACB 1799/4885 |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT2, SIRT1, SIRT6 | SMN1; SMN2 1298/4885NR1H4 3285/4885ACACB 268/4885 |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KDM1A, DOT1L, KDM1B | SMN1; SMN2 1978/4885NR1H4 1952/4885ACACB 2638/4885 |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | ADH1C, ALK, CYP26B1 | SMN1; SMN2 3224/4885NR1H4 642/4885ACACB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.